Zacks Investment Research cut shares of VWR Corporation (NASDAQ:VWR) from a buy rating to a hold rating in a research note published on Thursday.
According to Zacks, “VWR’s second-quarter earnings report was quite impressive, with both the top and the bottom line beating the Zacks Consensus Estimate. Geographically, the company recorded growth in Americas during the reported quarter driven by strong sales of equipment and instrumentation. Management is also looking forward to the long-term synergy benefits from the proposed merger with Avantor. The merger is expected to strengthen VWR’s business across the Americas and Europe. While we await the merger to close in the fourth quarter of 2017 we note that the stock price has already reached close to Avantor’s offer price and hence the short-term upside potential of VWR is limited now. On the flip side, a drop in EMEA-APAC sales was disappointing. Moreover, foreign currency was a major dampener. VWR’s poor margin scenario also raises concern.”
Several other brokerages also recently weighed in on VWR. ValuEngine raised shares of VWR Corporation from a hold rating to a buy rating in a research note on Wednesday, September 6th. BidaskClub downgraded shares of VWR Corporation from a sell rating to a strong sell rating in a research note on Saturday, September 2nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $31.67.
Shares of VWR Corporation (VWR) opened at 33.14 on Thursday. The company has a 50 day moving average of $33.03 and a 200-day moving average of $31.36. VWR Corporation has a one year low of $24.42 and a one year high of $37.25. The stock has a market cap of $4.37 billion, a price-to-earnings ratio of 30.69 and a beta of 1.19.
VWR Corporation (NASDAQ:VWR) last announced its earnings results on Monday, July 31st. The medical research company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.04. VWR Corporation had a net margin of 3.12% and a return on equity of 15.54%. The firm had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $1.16 billion. During the same quarter in the previous year, the company posted $0.42 EPS. The firm’s revenue for the quarter was up 2.2% on a year-over-year basis. On average, analysts anticipate that VWR Corporation will post $1.87 earnings per share for the current year.
WARNING: This report was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.chaffeybreeze.com/2017/09/17/vwr-corporation-vwr-cut-to-hold-at-zacks-investment-research.html.
A number of institutional investors and hedge funds have recently bought and sold shares of VWR. Capstone Asset Management Co. grew its holdings in VWR Corporation by 24.6% in the 1st quarter. Capstone Asset Management Co. now owns 10,670 shares of the medical research company’s stock valued at $301,000 after buying an additional 2,110 shares during the period. US Bancorp DE grew its holdings in VWR Corporation by 6.4% in the 1st quarter. US Bancorp DE now owns 55,764 shares of the medical research company’s stock valued at $1,573,000 after buying an additional 3,354 shares during the period. Bank of New York Mellon Corp grew its holdings in VWR Corporation by 5.7% in the 1st quarter. Bank of New York Mellon Corp now owns 465,569 shares of the medical research company’s stock valued at $13,129,000 after buying an additional 25,026 shares during the period. Swiss National Bank grew its holdings in VWR Corporation by 1.7% in the 1st quarter. Swiss National Bank now owns 151,519 shares of the medical research company’s stock valued at $4,273,000 after buying an additional 2,600 shares during the period. Finally, UBS Asset Management Americas Inc. grew its holdings in VWR Corporation by 42.7% in the 1st quarter. UBS Asset Management Americas Inc. now owns 65,313 shares of the medical research company’s stock valued at $1,842,000 after buying an additional 19,528 shares during the period.
About VWR Corporation
VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VWR Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR Corporation and related companies with MarketBeat.com's FREE daily email newsletter.